• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.

作者信息

Ricciuti Biagio, Metro Giulio, Baglivo Sara, Colabrese Daniela, Chiari Rita, Bennati Chiara, Paglialunga Luca

机构信息

Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.

Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.

出版信息

J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027.

DOI:10.1016/j.jtho.2016.12.027
PMID:28434516
Abstract
摘要

相似文献

1
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.一名非鳞状转移性非小细胞肺癌患者对纳武单抗的持久反应及免疫相关不良事件
J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027.
2
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.纳武利尤单抗在既往治疗的鳞状或非鳞状非小细胞肺癌中的疗效和安全性的暴露-反应分析。
Clin Cancer Res. 2017 Sep 15;23(18):5394-5405. doi: 10.1158/1078-0432.CCR-16-2842.
3
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.美国食品药品监督管理局批准摘要：纳武单抗用于治疗在铂类化疗期间或之后病情进展的转移性非小细胞肺癌。
Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16.
4
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.纳武单抗治疗晚期（转移性）非小细胞肺癌的安全性和疗效。
Expert Rev Anticancer Ther. 2016 Sep;16(9):903-10. doi: 10.1080/14737140.2016.1220836. Epub 2016 Aug 22.
5
Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer.非小细胞肺癌患者中血清抗谷氨酸脱羧酶抗体及HLA单倍型与纳武利尤单抗引发的1型糖尿病的关联
J Thorac Oncol. 2017 May;12(5):e41-e43. doi: 10.1016/j.jtho.2016.12.015. Epub 2016 Dec 23.
6
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.尼伏单抗相关胆管炎在非小细胞肺癌患者的影像学和临床病理特征。
Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20.
7
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.纳武单抗（一种抗程序性死亡蛋白1免疫检查点抑制剂）用于晚期难治性鳞状非小细胞肺癌患者的活性和安全性（CheckMate 063）：一项2期单臂试验
Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.
8
The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.非小细胞肺癌和肾细胞癌创新治疗的期权价值。
Am J Manag Care. 2017 Oct 1;23(10):e340-e346.
9
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.非小细胞肺癌患者接受纳武单抗治疗期间出现的与抗程序性死亡蛋白1相关的冷球蛋白血症。
Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.
10
Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.一例转移性非小细胞肺癌患者中出现的晚期发生的nivolumab诱导的隐源性机化性肺炎，酷似肺部进展。
Eur J Cancer. 2017 Nov;85:155-157. doi: 10.1016/j.ejca.2017.07.049. Epub 2017 Sep 13.

引用本文的文献

1
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.延长nivolumab 的给药间隔：未选择癌症患者的基于模型的模拟。
Br J Cancer. 2024 May;130(11):1866-1874. doi: 10.1038/s41416-024-02659-x. Epub 2024 Mar 26.
2
Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.免疫检查点抑制剂的神经眼科并发症：一项系统综述
Eye Brain. 2020 Nov 3;12:139-167. doi: 10.2147/EB.S277760. eCollection 2020.
3
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.
免疫治疗停药后的延迟免疫相关事件（DIRE）：远处自身免疫的诊断危害。
J Immunother Cancer. 2019 Jul 3;7(1):165. doi: 10.1186/s40425-019-0645-6.